Prime Medicine Reports Full Year 2024 Financial Results and Provides Business Updates

-- On track to report initial data from Phase 1/2 clinical trial of PM359 for p47phox CGD in 2025 -- -- IND-enabling studies ongoing for PM577 for Wilson’s Disease; expect to file IND and/or CTA in 1H 2026 -- -- Additional high-value programs advancing through preclinical development -- CAMBRIDGE, Mass., Feb. 28, 2025 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today reported fina ...